Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 4, 2012 Navjot Kaur	Mead Johnson Comes Clean Mead Johnson likely to bounce back after its baby formula tested clean.
The Motley Fool January 7, 2009 Rick Aristotle Munarriz	5 Hot IPOs in 2008 With credit markets still tight and venture capitalists still shell-shocked, going public makes sense for a lot of private companies.
The Motley Fool November 17, 2009 Brian Orelli	Up 80%, It's Time to Sell Bristol-Myers to Mead Johnson: It's time to walk on your own. Investors will have an option of exchanging some or all of their Bristol-Myers shares for shares in Mead Johnson for a slight discount
The Motley Fool September 17, 2008 Brian Orelli	IPO? In This Market? Bristol-Myers continues with plans to spin off its nutritionals business.
The Motley Fool April 16, 2009 Rick Aristotle Munarriz	What's New on the Markets? Bridgepoint Education becomes the third successful IPO this year.
The Motley Fool June 7, 2006 Brian Gorman	Martek's Formula for Success Dependence on one customer could spell trouble for this nutritional supplement maker. Investors, take note.
The Motley Fool December 22, 2011 Rick Aristotle Munarriz	Recalls Dampen Holiday Cheer Wal-Mart and Target have holiday recalls on their hands.
The Motley Fool January 4, 2010 Rick Aristotle Munarriz	5 Biggest IPO Winners of 2009 Last year's hottest rookies are unlikely heroes.
The Motley Fool February 13, 2009 Rick Aristotle Munarriz	This Week's 5 Smartest Stock Moves Take a look at five smart business moves from last week: Successful IPO for Mead Johnson... Netflix passes the 10 million subscriber mark... Retail sales rose... Live Nation and Ticketmaster join forces... Guitar Hero publisher Activision rocks...
The Motley Fool January 28, 2009 Brian Orelli	A Mini-Pfizer in the Making Bristol-Myers Squibb looks like its setting itself up to be the next Pfizer.
The Motley Fool December 14, 2009 Rick Aristotle Munarriz	Rumble in the S&P 500 Jungle By the end of the trading week, Visa and Mead Johnson Nutrition will be added to the S&P 500, where they will take the place of Ciena and MBIA
The Motley Fool February 19, 2009 Robert Steyer	IPO Food for Thought The bosses at Pfizer should be interested in the recent Mead Johnson IPO so as to place a value on Wyeth's nutrition business.
The Motley Fool January 17, 2012 Brian Orelli	Pharma Focus Is Good For Your Portfolio Build your own portfolio.
The Motley Fool September 23, 2010 Brian Orelli	This Recall Should Bug You Abbott Labs announces a recall of some types of its Similac baby formula because it found beetles and their larvae in an area of one of its plants.
The Motley Fool June 30, 2010 Brian Orelli	Is Bristol-Myers Squibb a Buy? Bristol-Myers is a better buy than Eli Lilly for one major reason: its resources.
The Motley Fool December 17, 2009 Brian Orelli	This Acquisition Hears, Smells, and Tastes Soooo Good Johnson & Johnson picks up an ear, nose, and throat medical device maker.
The Motley Fool October 12, 2009 Robert Steyer	Healthy Spinoffs, Happy Investors When medical companies spin off unwanted divisions, the spinoffs can outperform the parent.
The Motley Fool March 22, 2010 Rick Aristotle Munarriz	4 Dividend Stocks Showing You the Money Mead Johnson Nutrition... Garmin... Prospect Capital... Guess?...
Financial Advisor October 2010 IPOs Are Back	IPOs Are Back Deal volume is up, but performance is iffy. Upcoming deals include GM, LPL and maybe Facebook.
The Motley Fool May 3, 2011 Dan Caplinger	Be a Smarter IPO Investor Some IPOs soar and others bomb. Be aware of the traps.
The Motley Fool January 29, 2010 Brian Orelli	All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time.
The Motley Fool August 11, 2010 David Meier	Does Bill Miller Think Johnson & Johnson Is Attractive? Johnson & Johnson fits Miller's criteria perfectly. It pays a 3.6% dividend that has been growing 11.1%, on average, for the past five years.
The Motley Fool August 11, 2009 Brian Orelli	A Drug Stock IPO! Finally! Today's offering, Cumberland Pharmaceuticals is in a special breed of small drugmakers: it's actually profitable.
The Motley Fool July 2, 2009 Brian Orelli	Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company.
The Motley Fool September 15, 2011 Brian Orelli	Stop Worrying About Pfizer's Breakup Sometimes you just have to trust management.
The Motley Fool April 3, 2009 Rick Aristotle Munarriz	Come On In, the Water's Fine The time is ripe for new IPOs.
The Motley Fool January 18, 2011 Russ Krull	Keep It or Sweep It: Johnson & Johnson? Should the company be held or sold?
The Motley Fool November 30, 2011 Travis Hoium	What Is a Good IPO? The success of an IPO really depends on your point of view.
The Motley Fool November 20, 2008 Rick Aristotle Munarriz	Go Public, Get Schooled Online educator Grand Canyon Education did what no company has dared to do since early August: It went public.
The Motley Fool May 28, 2008 Dayana Yochim	Stocks Aren't Just for Grownups It's never too early to start saving. Invested wisely, those $50 birthday checks can turn into a pile of money over the years.
The Motley Fool March 12, 2009 Rick Aristotle Munarriz	The Military Secret That Can Make You Rich Shares of online educator American Public Education rise 7% after the company posts an inspiring quarterly report.
The Motley Fool February 22, 2010 Alex Dumortier	7 Stocks Hedge Funds Like Hedge funds were battered by losses and investor redemptions during the worst of the financial crisis, but now that the industry has regained some of its swagger, it might be worth asking: Which stocks has the "smart money" been buying?
The Motley Fool December 17, 2008 Selena Maranjian	The Sweet and Sour of IPOs Getting in on an IPO early is no surefire path to riches. It's usually best to wait until the dust settles and you have enough information to be very confident in the company's future.
The Motley Fool January 26, 2011 Brian Orelli	J&J Will Recover -- Someday Consumer health care might be the smallest of Johnson & Johnson's three divisions, but the 15% drop in revenue still hurts. A lot.
The Motley Fool February 4, 2010 Brian Orelli	A Drugless Drugmaker IPO! Biotech investors embrace risk ... sort of. The most exciting thing about Ironwood's IPO? The company doesn't have any drugs on the market.
The Motley Fool February 17, 2011 Alex Dumortier	Seize Your Chance to Beat the Pros! An area of genuine opportunity for the small investor. Spinoffs remain an underappreciated area in which the individual investor actually gains an edge over institutions.
The Motley Fool November 17, 2005 W.D. Crotty	SunPower Shines The solar cell manufacturer soars 40% above its initial offering price. Cypress Semiconductor is the big winner here. Even at the IPO price, its stake in SunPower is now valued at a dazzling $936 million.
The Motley Fool May 12, 2010 Nick Kapur	J&J: A Winner on Both Sides of the Ball (Fool TV) If you're looking to build a dynasty in your portfolio, you'd be hard-pressed to find a better-balanced outfit than veteran Johnson & Johnson. The consumer products giant is discussed in this video.
BusinessWeek August 13, 2009 Peter Carbonara	Look at All the New IPOs More private companies are going public -- and the new companies are outperforming blue chips.
The Motley Fool March 3, 2009 Rick Aristotle Munarriz	Why Aren't Facebook and Twitter Public? The markets need these two companies more than they need the markets.
The Motley Fool July 12, 2011 Todd Wenning	What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors.
The Motley Fool June 10, 2004 Rich Smith	Big Business' Influential Formula Troubled by government ads promoting breast-feeding, baby formula companies get a controversial reprieve.
The Motley Fool May 28, 2010 Brian Orelli	How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem?
The Motley Fool July 8, 2011 Brian Orelli	Half a Breakup Is Better Than No Breakup at All Pfizer keeps two divisions and puts two on the chopping block.
The Motley Fool August 19, 2010 Brian Orelli	Buffett Is Buying J&J. Should You? It depends on your time horizon.
The Motley Fool August 28, 2010 Todd Wenning	Dividend Report Card: Johnson & Johnson Does this health-care titan's dividend pass the test?
The Motley Fool March 22, 2006 Dayana Yochim	Stocks Aren't Just for Grown-Ups Help Junior turn those $10 birthday checks into a million dollars for the future.
The Motley Fool December 29, 2011 Matt Thalman	3 Companies That Give Back to Shareholders These three companies have consistently increased the value of each outstanding share: UPS... Johnson & Johnson... ExxonMobil...
The Motley Fool October 23, 2009 Brian Orelli	I Don't Need No Massive Merger Plavix's patent expiration is approaching, but Bristol-Myers Squibb is prepared.
The Motley Fool July 20, 2010 Brian Orelli	Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant.